Selexis, Pieris in Licensing Pact
By

By
Selexis, a Geneva, Switzerland-based life sciences company, has signed a license agreement that provides Pieris Pharmaceuticals, based in Boston, Massachusetts, access to Selexis’ SUREtechnology platform and SURE CHO-M cell line…

Asahi Glass Acquires German Biopharmaceutical CMO
By

By
AGC Asahi Glass (AGC), a Tokyo-based manufacturer of glass, chemicals, and high-tech materials, has acquired all shares of Biomeva from Biomeva Holding GmbH, a Heidelberg, Germany-based biopharmaceutical contract manufacturing organization.…

Merck & Co. Gets Priority Review for New Use of Lung Cancer Drug
By

By
Merck & Co. has received priority review from the US Food and Drug Administration for a supplemental biologics license application for Keytruda (pembrolizumab), the company’s anti-programmed cell death protein-1 therapy,…

Janssen Seeks EMA Approval for Once-Daily Dosing of HIV Therapy
By

By
Janssen-Cilag International, part of Johnson & Johnson, has submitted a marketing authorization application to the European Medicines Agency seeking approval for a new once-daily darunavir-based single tablet regimen (STR) for…

Novo Nordisk Voluntarily Recalls Select Batches of Diabetes Kit
By

By
Novo Nordisk has implemented a voluntary recall of six batches of the GlucaGen HypoKit (glucagon [rDNA origin] for injection) in the US due to two customer complaints from the UK…

GSK Submits RA Drug for European Approval
By

By
GlaxoSmithKline (GSK) has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the subcutaneous formulation of sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody for treating…

Takeda, MacroGenics End Autoimmune Drug Pact
By

By
Takeda Pharmaceutical Company has ended its license and option agreement for an anti-cancer drug candidate with MacroGenics, a Rockville, Maryland-based clinical-stage biopharmaceutical company focused on monoclonal antibody-based cancer therapeutics. MacroGenics…

GSK Divests Anesthesia Assets to Aspen
By

By
GlaxoSmithKline (GSK) has decided to divest its anesthesia portfolio to Aspen Pharma, based in KwaZulu-Natal, South Africa, for £180 million ($240 million) plus milestones of up to £100 million ($133…

Horizon Pharma to Acquire Raptor in Deal Valued at $800 Million
By

By
Horizon Pharma, a biopharmaceutical company based in Dublin, Ireland, has agreed to acquire Raptor Pharmaceutical, a Novato, California-based biopharmaceutical company, for $9.00 per share in cash, in a deal value…

Sanofi, Google’s Verily Launch Diabetes JV
By

By
Sanofi and Verily Life Sciences (formerly Google Life Sciences), an Alphabet company, have launched Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration. The joint venture is based…